Histidinol

Histidinol

SCHEMBL407337

N[C@H](CO)Cc1cnc[nH]1

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 6/20 0.61
HRH3 Q9Y5N1 6/20 0.61
ALDH1A1 P00352 3/20 0.61
NFKB1 P19838 2/20 0.61
MEN1 O00255 1/20 0.61
GLA P06280 1/20 0.61
KMT2A Q03164 1/20 0.61
CYP1A2 P05177 1/20 0.61
THPO P40225 1/20 0.61
LMNA P02545 2/20 0.59
APEX1 P27695 2/20 0.59
BLM P54132 1/20 0.59
CYP3A4 P08684 2/20 0.59
SLC7A5 Q01650 1/20 0.59
PKM P14618 1/20 0.55
KDM4E B2RXH2 1/20 0.53
POLB P06746 1/20 0.53
RECQL P46063 1/20 0.53
PMP22 Q01453 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidinol SCHEMBL6546332 1.00 HRH4 (0.61) HRH4HRH3ALDH1A1NFKB1MEN1
Histidinol SCHEMBL10002446 1.00 HRH4 (0.61) HRH4HRH3ALDH1A1NFKB1MEN1
Histidinol SCHEMBL29986891 0.98 HRH4 (0.62) HRH4HRH3ALDH1A1NFKB1MEN1
SCHEMBL13779893 0.82 HRH3 (0.63) HRH4HRH3ALDH1A1NFKB1MEN1
SCHEMBL4506698 0.81 HRH3 (0.61) HRH4HRH3ALDH1A1NFKB1MEN1
SCHEMBL12257052 0.81 HRH3 (0.67) HRH4HRH3ALDH1A1NFKB1MEN1
SCHEMBL6546327 0.81 HRH4 (0.61) HRH4HRH3ALDH1A1NFKB1MEN1
SCHEMBL21242759 0.81 HRH3 (0.61) HRH4HRH3ALDH1A1NFKB1MEN1
SCHEMBL11462720 0.81 HRH4 (0.61) HRH4HRH3ALDH1A1NFKB1MEN1
Bromide SCHEMBL11471002 0.79 HRH4 (0.59) HRH4HRH3ALDH1A1NFKB1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746091-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-09-05 US disclosed
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2023-02-02 US disclosed
US-11214548-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2022-01-04 US disclosed
US-20210188781-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2021-06-24 US disclosed
US-20200078358-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2020-03-12 US disclosed
US-20180354907-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2018-12-13 US disclosed
EP-3363788-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-08-22 EP disclosed
US-9944606-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2018-04-17 US disclosed
US-20170073370-A1 BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS, INC. 2017-03-16 US disclosed
US-20170073370-A1 BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS, INC. 2017-03-16 US disclosed
US-20140249073-A1 BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS, INC (US) 2014-09-04 US disclosed
US-20140249073-A1 BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS, INC (US) 2014-09-04 US disclosed
US-8778950-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2014-07-15 US disclosed
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2013-06-27 US disclosed
WO-2012166665-A2 BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS, INC. (US) 2012-12-06 WO disclosed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 US disclosed
WO-2012035346-A1 PRODRUGS OF GUANFACINE SHIRE, LLC (US) 2012-03-22 WO disclosed
US-20120065152-A1 PRODRUGS OF GUANFACINE SHIRE LLC (US) 2012-03-15 US disclosed
US-20120065152-A1 PRODRUGS OF GUANFACINE SHIRE LLC (US) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 HRH4 341/4885HRH3 255/4885ALDH1A1 3623/4885
US-20200078358-A1 Compounds and Methods for Treatment of Visceral Pain VIP, FABP2, FABP6 HRH4 793/4885HRH3 1229/4885ALDH1A1 603/4885
US-20120065152-A1 PRODRUGS OF GUANFACINE UGT1A6, GDA, UGT1A3 HRH4 3503/4885HRH3 3938/4885ALDH1A1 270/4885
US-20180354907-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 HRH4 341/4885HRH3 255/4885ALDH1A1 3623/4885
US-20140249073-A1 BROAD SPECTRUM ANTIBIOTICS SPAST, NPEPPS, SPOUT1 HRH4 4853/4885HRH3 4859/4885ALDH1A1 2541/4885
US-20170073370-A1 BROAD SPECTRUM ANTIBIOTICS SPAST, NPEPPS, SPOUT1 HRH4 4853/4885HRH3 4859/4885ALDH1A1 2541/4885
US-11746091-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 HRH4 341/4885HRH3 255/4885ALDH1A1 3623/4885
US-11214548-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 HRH4 341/4885HRH3 255/4885ALDH1A1 3623/4885
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain VIP, FABP2, FABP6 HRH4 793/4885HRH3 1229/4885ALDH1A1 603/4885
US-20210188781-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 HRH4 341/4885HRH3 255/4885ALDH1A1 3623/4885
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 HRH4 341/4885HRH3 255/4885ALDH1A1 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.